The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study

Canadian Journal of Cardiology

Volumn 32, Issue 2, 2016, Pages 169-176

  Lefebvre, Marie Claude D ^a,b   St Onge, Maude ^a,b   Glazer Cavanagh, Maude ^a,b   Bell, Laurence ^a,b   Kha Nguyen, John Nam ^a,b   Viet Quoc Nguyen, Patrick ^a,b   Tannenbaum, Cara ^b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTRE DE RECHERCHE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; DALTEPARIN; ENOXAPARIN; RIVAROXABAN; TINZAPARIN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CROSS-SECTIONAL STUDY; FEMALE; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; THROMBOEMBOLISM; VERY ELDERLY; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; FOLLOW UP; FRAIL ELDERLY; HEMORRHAGE; INCIDENCE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROCEDURES; QUEBEC; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; FRAIL ELDERLY; HEMORRHAGE; HUMANS; INCIDENCE; MALE; QUEBEC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; WARFARIN;

EID: 84959160821     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.05.012     Document Type: Article

References (40)

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
2. World Health Organization. Facts about aging, 2014. Available at: . Accessed November 4, 2014. http://www.who.int/ageing/about/facts/en/.
3. Clegg A., Young J., Iliffe S., Rikkert M.O., Rockwood K. Frailty in elderly people. Lancet 2013, 381:752-762.
4. Gary R. Evaluation of frailty in older adults with cardiovascular disease: incorporating physical performance measures. J Cardiovasc Nurs 2012, 27:120-131.
5. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
6. Verma A., Cairns J.A., Mitchell L.B., et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 2014, 30:1114-1130.
7. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
8. You J.J., Singer D.E., Howard P.A., et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e531S-e575S.
9. Go A.S., Hylek E.M., Borowsky L.H., et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999, 131:927-934.
10. Lau E., Bungard T.J., Tsuyuki R.T. Stroke prophylaxis in institutionalized elderly patients with atrial fibrillation. J Am Geriatr Soc 2004, 52:428-433.
11. Ogilvie I.M., Newton N., Welner S.A., Cowell W., Lip G.Y. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010, 123:638-645 e4.
12. Cherubini A., Corsonello A., Lattanzio F. Underprescription of beneficial medicines in older people: causes, consequences and prevention. Drugs Aging 2012, 29:463-475.
13. Maes F., Dalleur O., Henrard S., et al. Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation?. Clin Interv Aging 2014, 9:1091-1099.
14. Srivastava A., Hudson M., Hamoud I., et al. Examining warfarin underutilization rates in patients with atrial fibrillation: detailed chart review essential to capture contraindications to warfarin therapy. Thromb J 2008, 6:6.
15. Sanchez-Barba B., Navarrete-Reyes A.P., Avila-Funes J.A. Are geriatric syndromes associated with reluctance to initiate oral anticoagulation therapy in elderly adults with nonvalvular atrial fibrillation?. J Am Geriatr Soc 2013, 61:2236-2237.
16. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
17. Pisters R., Lane D.A., Nieuwlaat R., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138:1093-1100.
18. Perera V., Bajorek B.V., Matthews S., Hilmer S.N. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing 2009, 38:156-162.
19. Rockwood K., Mitnitski A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clin Geriatr Med 2011, 27:17-26.
20. Fried L.P., Tangen C.M., Walston J., et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56:M146-M156.
21. Moorhouse P., Rockwood K. Frailty and its quantitative clinical evaluation. J R Coll Physicians Edinb 2012, 42:333-340.
22. Rockwood K., Song X., MacKnight C., et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005, 173:489-495.
23. Bergman H., Ferrucci L., Guralnik J., et al. Frailty: an emerging research and clinical paradigm-issues and controversies. J Gerontol A Biol Sci Med Sci 2007, 62:731-737.
24. Ekerstad N., Swahn E., Janzon M., et al. Frailty is independently associated with short-term outcomes for elderly patients with non-ST-segment elevation myocardial infarction. Circulation 2011, 124:2397-2404.
25. Joseph B., Pandit V., Zangbar B., et al. Superiority of frailty over age in predicting outcomes among geriatric trauma patients: a prospective analysis. JAMA Surg 2014, 149:766-772.
26. Lee D.H., Buth K.J., Martin B.J., Yip A.M., Hirsch G.M. Frail patients are at increased risk for mortality and prolonged institutional care after cardiac surgery. Circulation 2010, 121:973-978.
27. Makary M.A., Segev D.L., Pronovost P.J., et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg 2010, 210:901-908.
28. Masud D., Norton S., Smailes S., et al. The use of a frailty scoring system for burns in the elderly. Burns 2013, 39:30-36.
29. Singh M., Stewart R., White H. Importance of frailty in patients with cardiovascular disease. Eur Heart J 2014, 35:1726-1731.
30. Denoel P., Vanderstraeten J., Mols P., Pepersack T. Could some geriatric characteristics hinder the prescription of anticoagulants in atrial fibrillation in the elderly?. J Aging Res 2014, 2014:693740.
31. De Breucker S., Herzog G., Pepersack T. Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study. Drugs Aging 2010, 27:807-813.
32. Lefebvre MC, St-Onge M, Bell L, et al. Reliability of a method to evaluate frailty using medical records of hospitalised octogenarians. J Am Geriatr Soc 2015;63:2407-8.
33. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010, 137:263-272.
34. McCormick D., Gurwitz J.H., Goldberg R.J., et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001, 161:2458-2463.
35. Reardon G., Nelson W.W., Patel A.A., Philpot T., Neidecker M. Warfarin for prevention of thrombosis among long-term care residents with atrial fibrillation: evidence of continuing low use despite consideration of stroke and bleeding risk. Drugs Aging 2013, 30:417-428.
36. Blodgett J., Theou O., Kirkland S., Andreou P., Rockwood K. Frailty in NHANES: comparing the frailty index and phenotype. Arch Gerontol Geriatr 2015, 60:464-470.
37. Cairns J.A., Connolly S., McMurtry S., et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011, 27:74-90.
38. Pilote L., Eisenberg M.J., Essebag V., et al. Temporal trends in medication use and outcomes in atrial fibrillation. Can J Cardiol 2013, 29:1241-1248.
39. Fang M.C., Go A.S., Chang Y., et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 2011, 58:395-401.
40. Gage B.F., Yan Y., Milligan P.E., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006, 151:713-719.